Intermountain Healthcare 738 Reviews - Salt Lake City Ut
Prog Community Health Partnersh. Author manuscript; bachelor in PMC 2021 Jan 1.
Published in final edited form as:
PMCID: PMC7751497
NIHMSID: NIHMS1652932
Trends in forbearance and retention associated with implementing a Medication Assisted Treatment program for people with opioid use disorders using a Commonage Impact approach
Kimberly D. Brunisholz
aneHealthcare Delivery Institute, Intermountain Healthcare, Salt Lake Urban center, UT
twoDivision of Epidemiology, Department of Internal Medicine, Schoolhouse of Medicine, University of Utah, Common salt Lake City, UT
Andrew Knighton
1Healthcare Delivery Plant, Intermountain Healthcare, Salt Lake City, UT
Amulya Sharma
fourDavis Behavioral Health, Ogden, UT
Lisa Nichols
threeCommunity Wellness, Intermountain Healthcare, Salt Lake City, UT
Kristen Reisig
4Davis Behavioral Health, Ogden, UT
Jed Burton
5Weber Human Services, Ogden, UT
Debbie Scovill
6Behavioral Wellness Clinical Program, Intermountain Healthcare, Salt Lake City, UT
Carolyn Tometich
6Behavioral Health Clinical Programme, Intermountain Healthcare, Salt Lake City, UT
Mark Foote
6Behavioral Wellness Clinical Plan, Intermountain Healthcare, Salt Lake City, UT
Shelly Read
6Behavioral Health Clinical Program, Intermountain Healthcare, Table salt Lake City, UT
Scott Whittle
7SelectHealth, Murray, UT
Abstract
Groundwork:
Medication Assisted Treatment (MAT) is an evidence-based program for patients with opioid use disorders. Withal, inside the state of Utah, MAT had non been widely bachelor, promoted, or adopted inside the public sector. Recognizing the potential benefit, a collective touch approach was used to promote social change and increase the utilization of MAT in the customs for handling of opioid use disorders.
Objective:
Conduct a retrospective, observational case series study to measure out the event of a community-based, collective bear upon approach implementing the MAT program to improve the charge per unit of abstinence and retention amongst individuals identified with an opioid use disorder in three Utah counties.
Methods:
The study was designed and implemented past the Utah Opioid Community Collaborative (OCC) using a collective touch arroyo, which included broad sector coordination (public-private collaboration), a common agenda, participation in mutually reinforcing activities, continuous communication, consistent measurement of results, and identification of a backbone organisation. The MAT intervention program includes use of FDA-approved medications in combination with counseling and behavioral therapies delivered inside 2 community sites. Assay was performed over time to depict the rate of abstinence and retention associated with participation in the MAT program during 2015–2017.
Results:
Of the 339 identified with risk of an opioid use disorders, 228 enrolled in the MAT Program. At MAT enrollment, average age was 32.6±8.2 years old and 58.0% were female. At 365 days post-MAT enrollment, 84% of participants were abstemious from opioid substances and 62% from all illicit substances.
Conclusions:
Utilization of a commonage impact approach provides a successful mobilization framework in Utah for increasing community date and expanding patient admission to under-resourced MAT programs while suggesting a high rate of abstinence from illicit substances at 12 months.
Keywords: community-based participatory inquiry, opioid apply disorder, collective impact, prevention, medication assisted handling
Introduction
Since the 1990'south, historical physician opioid-prescribing patterns accept been linked to opioid misuse and decease.1 Despite significant reductions in physician opioid prescribing since 2010two, opioid misuse persists and has accelerated among some populations, with increases in heroin and synthetic opioid deaths in contempo years.3,4 Approximately four% of US adults (aged 25 years and older) misuse prescription opioids, bookkeeping for more than 68% (47,600) of all drug overdose deaths in 2017 involving an opioid.5,6 From 2013–2015, Utah ranked 7th in the nation for drug overdose deaths per capita, led by prescription opioid overdose deaths, for which the state ranks 4th in the nation.4 While Utah is seeing a pass up in prescription opioid deaths since 2010—including a 12% decline in the contempo calendar year as reported by the Centers for Disease Control and Prevention (CDC), the number of heroin deaths increased during the same period.7,8 Healthcare utilization (i.east., emergency room visits and in-hospital admissions) for overdose related encounters has significantly increased during this time and continues to be highest among patients aged xviii–24.7 Despite national and state-wide efforts inside the wellness intendance organization to reduce opioid prescribing, the prevalence of opioid use disorders and related harms remains a primary public wellness concern.ix
Medication-assisted treatment (MAT) for patients with opioid employ disorders has proven effective in improving recovery and abstinence in randomized controlled trials versus psychosocial treatment lone.10 MAT, including opioid treatment programs, combines behavioral or psychosocial therapies, counseling and pharmacologically-approved medications to treat opioid utilize disorders. Amid medication-assisted treatment programs, buprenorphine, naltrexone, and methadone-based medication programs have been shown to be well-nigh effective with a high caste of prove for increased treatment retentivity and opioid misuse reduction.11,12 Retention in MAT programs among patients with opioid apply disorders is associated with better outcomes, fewer inpatient admissions of all types, and a reduction in wellness intendance expenditures and utilization of preventable services.13–16
Despite promising results, population access to MAT remains a barrier to reducing overdose deaths. Only 36,000 (4%) of the over 900,000 available physicians in the Usa able to prescribe opioids, have a waiver to prescribe buprenorphine to treat opioid use disorder, with express access particular to rural areas.17,18 Inadequate habit-related grooming, stigma associated with treating individuals who take opioid utilize disorders, unpredictable insurance coverage, along with a requirement of frequent check-in visits, drug monitoring tests and chronic prescription refills, brand it difficult to convince physicians alone to provide effective addiction care using MAT.xix In 2015, a national study reported that amongst states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people; and 38 states (77.half-dozen%) reported at least 75% of their Opioid Handling Programs were operating at 80% chapters or more.20 Therefore, the motivation for MAT participation exists; however, there are a lack of programs and health professionals able to provide access to MAT. Every bit such, the scale and depth of the opioid crisis has proven to exist a thorny problem—a trouble that requires an "ecosystem of collaboration" to address a community's needs.21
Collective impact methods, grounded in coalition activity theory, is a framework to "tackle deeply entrenched and complex social problems" and is premised on the belief that no single policy, regime, establishment, or programme can accomplish pregnant and lasting social alter without each other.22 Collective impact was created as a movement or action framework to help problem solve and mobilize complex social change; community-based participatory research (CBPR), a gratis framework used specifically for conducting research, is characterized by principles on how to engage communities in the research procedure.23 Deliberate written report using CBPR evaluation methods has the potential to provide a coherent representation of how mobilization and collective activeness is gradually developed and leads to systematic changes in health priorities for communities.23 A systematic review performed by Anderson et al., suggested that coalition-led interventions benefit a diverse range of individual health outcomes and behaviors, as well equally health and social care delivery systems.24 Leveraging the full resources and collective activeness of a community—including partnership among public, private, and not-for-profit organizations like health systems—has undoubtedly become a critical path to futurity progress to combat the opioid epidemic.25,26
Nonetheless, the ability to assess the effects of a community-based partnership to reduce the opioid crisis has non been demonstrated. To address these gaps in knowledge, this report characterizes the development and deployment of a MAT demonstration project as part of a broader collective bear upon approach to identify, prioritize and accost the root causes of prescription opioid misuse, addiction and overdose deaths in Utah communities while improving access to care. This paper briefly describes the system of the Opioid Community Collaborative (OCC), evolution of the MAT sit-in project and the differences in abstinence and retention outcomes over discrete treatment periods in the MAT program for individuals identified with an opioid use disorder.
Methods
Developing the Collective Affect Arroyo: The Opioid Community Collaborative (OCC)
Prescription opioid addiction stems from numerous causes and requires multifaceted interventions involving multiple stakeholders to impact health outcomes. Recognizing the need for a community-based, participatory action approach for intervention development, the Utah Department of Wellness, Weber Human Services (WHS), Davis Behavioral Wellness (DBH), multiple local community agencies, and anchor institutions such as Intermountain Healthcare (Intermountain), formed the Opioid Customs Collaborative (OCC) in 2015. (Table 1)
Table 1-
List of Opioid Community Collaborative (OCC) Partners
| Opioid Customs Collaborative Partners |
|---|
| Intermountain Healthcare (Co-Chair) |
| Davis Behavioral Health (Co-Chair) |
| Utah Department of Health |
| Weber Human Services |
| Committee on Criminal and Juvenile Justice |
| Local Prevention Coordinating Councils |
| Local Pharmacies |
| Federally Qualified Health Centers |
| Utah Toxicant Control Center |
| Health Insurers |
| Academy of Utah |
| Use Merely every bit Directed Campaign |
| Utah Division of Substance Corruption and Mental Health |
| Utah Naloxone |
The charter of the OCC was to work equitably as partners using existing community assets to programme, implement and study strategies to decrease the brunt of pharmaceutical opioid misuse, addiction, and overdose deaths in Utah communities. OCC members agreed to a common agenda, participation in mutually reinforcing activities, continuous communication, consistent measurement of results, and identification of a backbone organisation to accept on the role of managing the community collaboration.22 The strategies developed by the membership of the OCC are reported elsewhere and include awareness, physician prescribing practices, and treating opioid utilise disorders.26
Role of Member Organizations in the Opioid Customs Collaborative
A collaborative structure was organized for the OCC including alignment with a state-led coalition (Utah Coalition for Opioid Overdose Prevention), OCC steering committee, and committees focused on the three mutual OCC objectives including a policy informational committee. (Figure i). Committees were facilitated by different OCC members and included membership from partner organizations that utilized participation from laypersons affiliated with community organizations. Best clinical practices for opioid sensation, opioid prescribing, and opioid utilize disorder treatment were shared within committees and within organizations to interpret and generalize cognition generated within the OCC structure. Each OCC fellow member was responsible for upholding the guiding principles of the collective action framework.
Collaboration and alignment construction of the Opioid Community Collaborative
Members of the OCC identified limited access to treatment options for opioid apply disorders as a primary barrier to treatment. OCC stakeholders contributed by developing a care process model, or clinical workflow, for the MAT program that included deliberate, standardized screening and treatment (pharmacologic and non-pharmacologic) guidelines over the class of the plan. Local community sites adapted the care process to fit their local needs and population. In addition, OCC stakeholders helped to develop data collection processes and ascertain information measures to rails improvements over time. Finally, OCC stakeholders collectively met monthly to share lessons learned and ideas for comeback, to review real-fourth dimension data through audit and feedback dashboarding, and to review future strategic priorities such equally sustainability and scale for other settings and community groups. As a backbone arrangement, Intermountain committed $500,000 per year to fund a three-yr, community-based demonstration project to examination the effectiveness of a MAT program combined with counseling and recovery supports in reducing opioid dependence.
Medication Assisted Treatment (MAT) Program Intervention
MAT is the use of FDA-approved medications in combination with counseling and behavioral therapies, to provide a "whole-patient" approach to the treatment of substance use disorders.27 Patients can be referred from a number of settings: a treating healthcare provider, court-ordered to attend, from other community professionals (including OCC organizations similar the county jail), clergy, family/friends or be self-referred into the programme. The clinical staffing structure for the MAT plan includes a treating medico, a registered nurse, a licensed clinical social worker/care coordinator, and a licensed practical nurse. Individuals were screened for eligibility and then enrolled inside the program. The clinical team considers MAT if a patient shows signs of mild to moderate withdrawal. In addition to MAT, the program as well includes: i) psychosocial services, 2) education, outreach and recovery supports, and three) coordination/integration of intendance. All intendance components of MAT (pharmacologic and not-pharmacologic) are delivered in the same setting (ex. DBH or WHS) past members of its clinical team and practise non apply a collaborative opioid prescribing model linking opioid treatment programs with office-based buprenorphine providers.28 Patients are retained in the programs for as long as needed. However, at 12 months, the MAT team together with the patient reviews progress made and determines if long-term maintenance or tapering pharmacologic therapy with belch or "transition" from the plan is suggested. Each discharge process is individualized, a successful one defined by achieving 75% of the individual handling goals fix by the patient and the MAT clinical team.
Target Population and Community MAT Settings
The target population for the MAT intervention, as defined by the OCC community participants, included all insured, underinsured and uninsured individuals living in Utah'south Davis, Weber and Morgan, counties identified with an opioid apply disorder with a specific emphasis on serving meaning women and people at-adventure for or experiencing homelessness. In Utah, Medicaid patients receive behavioral wellness intendance through a county-level Mental Health Authority that both coordinates commitment of behavioral health and substance utilize disorder services and administers wellness plan financing. Davis Behavioral Health (DBH) and Weber Human Services (WHS), organized under a cooperative agreement between Davis, Weber and Morgan (Utah) county governments, were selected to administer the MAT program to the target populations. For context, the Utah Medicaid programme does embrace methadone treatment for individuals in need, and the country of Utah did not take Medicaid expansion at the time of this analysis.
Adult individuals (anile ≥18 years) referred to DBH or WHS locations were identified as candidates for the MAT programme if they were identified with an opioid apply disorder. Opioid hazard was defined past the NIDA Quick Screen Question, the NIDA Modified Help two.0 screening exam, or past discretion of the treating provider. Any persons indicating "yes" to the use of illegal or prescription drugs for non-medical reasons in the concluding 12 months, besides with a substance involvement score ≥3 measured in the last 3 months, received an assessment to validate an opioid utilize disorder and the need for medication-assisted treatment. Additionally, to exist included in the study, subjects had to: 1) exist a Davis, Weber, or Morgan County resident, 2) be willing to attend counseling in addition to MAT, and 3) have at to the lowest degree one Urine Analysis (UA) laboratory examination completed during the MAT programme. Individuals were excluded from the study if they: 1) had any contraindication to buprenorphine, naltrexone, methadone, or naloxone, two) were seeking pain direction, or three) exhibited dangerous behavior to the staff or others. Additionally, provider capacity issues were considered at the time of enrollment, which may take excluded boosted individuals from enrollment and thus, participation in the written report.
Individuals who met the inclusion/exclusion criteria were further delineated into two study groups: a Brief MAT (B-MAT) cohort including individuals with at to the lowest degree 90 days of enrollment and an Extended MAT (E-MAT) cohort including individuals with at least 365 days of enrollment inside the MAT plan. All participants in the Due east-MAT cohort were besides reported in the B-MAT accomplice. This stratification was purposively selected to describe the MAT results early within a person's handling journeying (within xc days) when the main goal of MAT is to stabilize their opioid exposure, while suppressing and mitigating craving and withdrawal symptoms. Additionally, results were reported within a group of patients who had longer term exposure to the MAT program—those successfully retained for 12 months—to describe the program outcomes amidst those beingness considered at that time for discharge or transition from the program.
Information Collection/Measurement.
Information were included from July 2015 through Oct 2017. All data were reported and extracted using electronic medical records from DBH and WHS facilities including demographics, handling encounters, medications, clinical characteristics, and laboratory data. The main endpoints were abstinence and retentivity in the program when enrolled in MAT. Abstinence was measured using a standard 12-console UA laboratory exam to discover any amphetamines, barbiturates, benzodiazepines, cocaine, ecstasy, heroin opiates, marijuana, methadone, methamphetamines, oxycodone HCI, phencyclidine (i.due east., PCP) and propoxyphene. Laboratory results were analyzed for presence of: 1) opioids only and 2) all substances including opioids only excluding amphetamines (methamphetamines were non excluded). Abstinence was measured as the percentage of UA laboratory exam results that were negative (from the substances listed to a higher place) over the full tests conducted (negative UA tests/full UA tests). Amphetamines were excluded because this medication form can likewise be prescribed for treatment of other mental health conditions, one's quite common among participants. UA laboratory tests were analyzed over the form of the MAT program. Retention in the program was measured by the percentage of patients who remained engaged in medical treatment and therapy over the full patients that started treatment. Patients may have left the treatment group if they were discharged, transferred, deceased, incarcerated or had prolonged inactivity.
Secondary endpoints included the: 1) median number of UA tests per patient, 2) percentage of patients with at least one UA test, and 3) percentage of successful versus unsuccessful discharges measured over time for each cohort to bear witness treatment impact and document a baseline in care for MAT participants. A successful belch was defined by achieving 75% of the individual treatment goals ready by the patient and the MAT clinical team. Health outcomes such as death during MAT enrollment were also tracked. Self-reported data was included on living conditions and employment affect, categorized as "improved, aforementioned, or worse" and measured at 3 and 12 months in the MAT program.
Demographic data was self-reported at treatment program enrollment and included: age (in years), sexual activity (defined equally male, female, or unknown/unreported), race/ethnicity, insurance payer type (i.e., uninsured, Medicaid, or commercial insurance), percent of federal poverty line, employment condition (defined as unemployed, employed, disabled, homemaker, student, retired, unknown), and living system condition (defined equally individual residence, jail/correctional facility, homeless, 24-60 minutes residential care facility). Individuals living in a 24-hr residential care facility or a jail/correctional facility were transported to the MAT program locations for participation.
Statistical Assay.
Summary statistics were used to draw the study participant characteristics. Main measures were computed for all eligible patients with at least one urine test during treatment. All patients were diagnosed as positive for opioids and all-illegal substances on their first test. The urine test results were plotted over 30-day intervals for those in the B-MAT cohort and over 90-day intervals for patients in the E-MAT cohort. To place the abstinence trend for opioids but and all substances, univariate linear regression was performed. To measure retentivity, B-MAT patients were assessed for agile date at 30-24-hour interval intervals since treatment enrollment, and Eastward-MAT patients were assessed for active engagement at ninety-twenty-four hours intervals since treatment enrollment. Time intervals were pre-determined and selected past the OCC membership equally the best method to monitor the performance of the MAT over time. Rates of abstinence and retention were visualized in line graphs plotted over time to assistance detect trends, shifts, or patterns in performance. This enquiry written report was approved by the Department of Human Services, State of Utah Institutional Review Board, and the Intermountain Healthcare's Institutional Review Board.
Results
Of the patients screened for the MAT program, 339 met study inclusion/exclusion criteria and 288 enrolled into the MAT programme during the study menses. Of these, 186 attended the MAT programme at DBH and 102 at WHS. Fifty-one patients were excluded from the report because results from UA tests were non collected electronically in the get-go of the MAT program. Of those enrolled, 56% (n=288) had enrolled in the MAT plan for ≥90 days (B-MAT cohort), and 44% (due north=221) had enrolled in the MAT plan for ≥365 days (Eastward-MAT cohort).
Baseline demographics are summarized in Table 2. At MAT enrollment, the boilerplate MAT participant was 32.6±8.2 years old with 58.0% being female. MAT participants were 87.5% white, and ix.4% were of Hispanic or other ethnic background. Participants tended to be uninsured (73.6%); withal, eighteen.4% had Medicaid insurance and 8.0% had commercial insurance. Over 64.ii% of the MAT participants had an income level below 100% of the federal poverty level. A majority of participants were unemployed (51.3%) or disabled (7.three%), while only 37.7% were actively employed. Most MAT participants resided in a individual residence (ninety.6%); nonetheless, 5.7% were enrolled from a jail or a correctional facility, and 2.four% reported homelessness. Of the MAT participants, thirteen.4% were meaning (due north=38). In that location were no clinically meaning differences between the B-MAT cohort and Eastward-MAT cohort participants.
Table two-
Demographic and social economic characteristics of participants in the Medication Assisted Handling Program
| Information Variables | Medication Assisted Treatment (MAT) Program Participants | |||
|---|---|---|---|---|
| B-MAT† cohort:Enrolled ≥ 90 Days | E-MAT* cohort: Enrolled ≥ 365 Days | |||
| n=288 | due north=221 | |||
| n | Mean± SD or % | north | Mean± SD or % | |
| Average age, years | 288 | 32.vi±8.2 | 221 | 32.9±seven.6 |
| Historic period Categories | ||||
| 18 to 24 | 39 | thirteen.54% | 25 | 11.31% |
| 25 to 34 | 131 | 45.49% | 99 | 44.lxxx% |
| 35 to 44 | 80 | 27.78% | 69 | 31.22% |
| 45 to 64 | 38 | 13.nineteen% | 28 | 12.67% |
| Gender | ||||
| Female | 167 | 57.99% | 131 | 59.28% |
| Male person | 121 | 42.01% | 90 | twoscore.72% |
| Ethnicity | ||||
| Non Hispanic | 261 | 90.63% | 204 | 92.31% |
| Hispanic | 22 | 7.64% | 13 | v.88% |
| Mexican | iii | 1.04% | three | 1.36% |
| Puerto Rican | 1 | 0.35% | 1 | 0.45% |
| Unknown | one | 0.35% | 0 | 0.00% |
| Race | ||||
| White | 252 | 87.fifty% | 197 | 89.14% |
| Other single race | 24 | 8.33% | 15 | half-dozen.79% |
| American Indian | 6 | 2.08% | 4 | 1.81% |
| Two or more races | 3 | ane.04% | iii | one.36% |
| Asian | two | 0.69% | two | 0.xc% |
| Unknown | 1 | 0.35% | 0 | 0% |
| Insurance | ||||
| Uninsured | 212 | 73.61% | 162 | 73.30% |
| Medicaid | 53 | 18.40% | 43 | 19.46% |
| Commercial | 23 | 7.99% | sixteen | 7.24% |
| Socio-Economic Status (100% of FPL ‡ ) | ||||
| Below | 185 | 64.24% | 140 | 63.35% |
| To a higher place | 103 | 35.76% | 81 | 36.65% |
| Employment Status | ||||
| Unemployed | 146 | 50.69% | 115 | 52.04% |
| Employed | 110 | 38.19% | 82 | 37.10% |
| Disabled | twenty | 6.94% | 17 | 7.69% |
| Homemaker | 8 | 2.78% | 4 | 1.81% |
| Student | 2 | 0.69% | 1 | 0.45% |
| Retired | 1 | 0.35% | 1 | 0.45% |
| Unknown | one | 0.35% | 1 | 0.45% |
| Living Arrangement Status | ||||
| Private Residence | 260 | xc.28% | 201 | 90.95% |
| Jail or correctional facility | 15 | 5.21% | fourteen | half dozen.33% |
| Homeless | 7 | ii.43% | 5 | 2.26% |
| 24-hr residential intendance | 4 | 1.39% | 1 | 0.45% |
| Unknown | 2 | 0.69% | 0 | 0% |
| Pregnant Women | 38 | 13.xix% | 30 | thirteen.57% |
Equally described in Figure two, 75% were abstemious from opioid substances and 59% from all illegal substances institute on UA tests for those with 90 days of MAT program enrollment (abstinence was measured as the percentage of UA laboratory test results that were negative over the full tests conducted). For those with at to the lowest degree 365 days of MAT enrollment, 84% of participants were abstinent from opioid substances and 62% from all illegal substances. Figure 3 demonstrates a 94% retention rate for participants who have been enrolled for at least ninety days and 58% retention rate for participants enrolled at least 365 days.
Abstinence was measured by the rate of negative Urine Assay laboratory tests over the number of total tests during the days in the plan period. Figure 2A represents participants in the Brief Medication Assisted Treatment (B-MAT) cohort with ≥xc days of enrollment. Figure 2B represents participants in Extended Medication Assisted Treatment (E-MAT) cohort with ≥365 days of enrollment. All participants in the E-MAT cohort were also reported in the B-MAT cohort.
Retention in the Medication Assisted Treatment programme was measured by the percent of patients that remained engaged in pharmacological treatment and psychosocial services over the total patients that started treatment. Figure 3A represents participants in the Brief Medication Assisted Treatment cohort with ≥90 days of enrollment. Figure 3B represents participants in the Extended Medication Assisted Handling (E-MAT) cohort with ≥365 days of enrollment. All participants in the E-MAT accomplice were also reported in the B-MAT cohort.
Secondary outcomes are reported in Table three. Trends over fourth dimension in the plan suggest an increment in the median number of UA tests per patient, an increment in the percent of patients with at least 1 UA test, and the count of successful discharges. Unsuccessful discharges were relatively small (n=12) in the first 90 days of the program nonetheless, substantially higher across 90 days (north=58). MAT participants self-reported improvements in living conditions (58%) and employment (66%) after participating in the program. One patient died during MAT participation though the cause of death was not attributable to the pharmacologic handling or psychosocial services.
Table 3-
Secondary outcomes associated with the Medication Assisted Treatment (MAT) Plan.
| Medication Assisted Handling (MAT) Program Participants | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| B-MAT† accomplice: Enrolled >=xc Days | Eastward-MAT* cohort: Enrolled >=365 Days | ||||||||
| n=288 | north=221 | ||||||||
| Patients | Day 0 | @ Day xxx | @ 24-hour interval threescore | @ Mean solar day 90 | Mean solar day 0 | @ Day 90 | @ Mean solar day 180 | @ Day 270 | @ Day 365 |
| Enrolled and attention MAT (in treatment) | 288 | 284 | 279 | 271 | 221 | 213 | 188 | 154 | 127 |
| Successfully Discharged | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | xx |
| Unsuccessfully Discharged | 0 | 1 | five | 12 | 0 | 7 | 25 | 48 | 65 |
| Transferred | 0 | 2 | 3 | iv | 0 | 0 | iv | 6 | 8 |
| Died | 0 | ane | 1 | 1 | 0 | 1 | one | i | ane |
| Full Patients | 288 | 288 | 288 | 288 | 221 | 221 | 221 | 221 | 221 |
| Urine Assay (UA) | Mean solar day 0 | Day 1–thirty | Day 31–lx | Day 61–90 | Day 0 | Day 1–ninety | Twenty-four hour period 91–180 | Day 181–270 | 24-hour interval 271–365 |
| # of Patients | 288 | 193 | 182 | 177 | 221 | 176 | 151 | 132 | 100 |
| # of Tests | 290 | 574 | 530 | 482 | 222 | 1159 | 894 | 738 | 625 |
| # of Negative tests: opioid substances | 0 | 414 | 410 | 363 | 0 | 862 | 708 | 588 | 523 |
| # of Negative tests: All illegal substances | 0 | 306 | 312 | 283 | 0 | 645 | 526 | 438 | 388 |
| Measures | |||||||||
| Median Tests per Patient | ane | iii | iv | 4 | 1 | viii | viii | seven.five | eight |
| Pct patients with at least 1 UA exam | 100% | 68% | 65% | 65% | 100% | 83% | 80% | 86% | 79% |
| % Negative UA tests for opioid substances | NA | 72% | 77% | 75% | NA | 74% | 79% | 80% | 84% |
| % Negative UA tests for all illegal substances | NA | 53% | 59% | 59% | NA | 56% | 59% | 59% | 62% |
| Count of successful discharges | 0 | 0 | 0 | 0 | 0 | 0 | 3 | nine | viii |
| Count of unsuccessful discharges | 0 | i | 4 | vii | 0 | vii | 18 | 23 | 17 |
Discussion
Addressing the root causes of opioid dependence using a commonage affect approach led to improvements in access to scarce MAT program resources in three Utah counties. The results of this study uniquely demonstrate the effects of an prove-based MAT plan deployed using partnership and collaboration taking grade in the healthcare industry to solve the community'southward nigh pressing problems. Engaging a wide grouping of aligned community organizations and a backbone or "integrator" (i.due east., Intermountain) to hold the whole and create a infinite for aligned action while attacking the problem of opioid-employ disorder, demonstrated that patient participation in a customs-based MAT programme resulted in promising abstinence rates upward to 1 year following enrollment (84%). The results of this written report also provided a structured baseline to document the process of intendance for MAT participants, which was unknown (i.east. enrollment totals, median tests per patient, successful/unsuccessful discharges) and allowed OCC members and clinical care teams to understand if care processes were changing over time. Further, many of the participants self-reported improvements in living conditions and employment suggesting return to customary living standards. Of contempo, the Centers for Disease Control and Prevention reported that there was a 12% decline in fatal overdoses in Utah over a one-year period catastrophe in Jan 2018—instance avoidance statistics that may be associated with the statewide OCC collaborative model and will crave farther program evaluation.8
Utilizing a collective impact approach to implement the MAT program in community settings demonstrated hope for a healthcare system focused on promoting health and well-beingness in communities, while also strategically building capacity and adequacy within community-based organizations. This study demonstrated comparable rates of abstinence and retention amongst a predominately underserved, vulnerable population compared to other published healthcare-based strategies.12,19,29,30 These results are hypothesized to have emerged considering of the key pillars of the community approach. Outset, the OCC partnership was structured as a learning collaborative assuasive stakeholders to human action quickly to incorporate new ideas from a variety of settings and disciplines into daily practice. Second, the OCC crossed multiple sectors and institutions, cocky-selecting teams and individuals that were highly effective and passionately connected to the health priority, assuasive piece of work to progress in concert rather in isolation, and providing unique perspectives to address difficulties. Third, challenges in implementing MAT within the community settings were addressed with customized support. By working alongside OCC members, the emerging needs of the community partners were addressed with tailored support and resources instead of a mass-produced solution. Based on the success of the OCC partnership and the early results of this study, nosotros surmise that this arroyo could exist generalized to other urgent health priorities based in communities such every bit initiatives to prevent deaths from suicide and to mitigate the effects of social determinants on health and well-existence.
Nevertheless, even with this success, key lessons were identified by the OCC as the MAT program was implemented to better access to treatment for prevention of opioid-use disorders. OCC stakeholders learned along the way to proceed vigilantly, focusing time and endeavour on the most promising practices or care processes within their own wheelhouse. For example, equally an integrated delivery arrangement, Intermountain was more than suited to act as a backbone organization rather than every bit the MAT service provider because local mental health providers were already geographically situated in the communities, specialized in addiction medicine, already existed to provide mental wellness services to a high proportion of their community members and were less stigmatized in their provision of MAT. The health system in return provided credibility and anchoring to the OCC—including the foresight to work with community partners to maintain programs once grant funding expires. This lesson documents the demand to recognize and mobilize community assets that be and may be underutilized outside of an individual healthcare system to efficiently progress towards coming together community-wide goals. Additionally, organizing the OCC took considerable fourth dimension and resources to ensure a consistent care process was delivered at multiple discrete sites—resources that must be maintained over time to sustain the gains in health outcomes amidst participants. Identifying capable leaders within the healthcare system and in community organizations that can act as clinical champions, while sustaining these customs relationships, is essential especially amidst multiple overlapping priorities and goals. Besides, recognizing that clinical champions did not necessarily need to be traditional wellness professionals such equally a physician or a nurse leader; licensed social workers and care coordinators were responsible for implementing much of the MAT program at county locations. Finally, evaluating the bear on of a collaborative solution such as MAT was challenged, particularly when identifying and defining commonage measures of success and information sharing among independent health organizations—an essential component of tracking and monitoring health.
Limitations.
Several limitations should be considered when interpreting the study results. First, despite attempts to include all referred clients who enrolled with the MAT programme within a three-county area in Utah, generalizability to a population exterior of this area may be difficult due to differences in underlying community characteristics, lack of established organizational partnerships, and alignment of county priorities. 2nd, we exercise not all the same know if the effects have persisted beyond the time catamenia outlined in the study though longitudinal plan evaluations are planned. 3rd, data that was non electronically captured in the study (i.e., outset UA exam results and NIDA screening assessments) is not bachelor for data collection. In conjunction with this limitation, participants were only required to have 1 UA exam to be considered eligible for study. However, among those that participated for at to the lowest degree 12 months, close to 80% of participants had UA tests in all time periods from enrollment suggesting a consistent clinical exercise among participants and sites. Additionally, intermediate health outcomes (e.1000. relapse/overdose), astute care utilization (e.m. ED visits or hospitalizations), or social outcomes (east.one thousand. arrests) accept also been associated with persons who have opioid use disorder seeking treatment only were non bachelor for study. Finally, as this was a retrospective, observational instance serial report employed to draw conditional outcomes associated with participation in the MAT program, no comparator or control group was used. Further enquiry is needed to compare the effectiveness of MAT—a programme with a multi-faceted approach to treat opioid-use disorder—with more traditional programs focused more exclusively on psychosocial therapy.
Conclusion.
Commonage impact provides a successful mobilization framework in Utah for increasing customs engagement and expanding patient access to under-resourced MAT programs. Further research is needed to determine if positive results are sustained when comparing the effectiveness to other proven psychosocial methods and more globally if the strategies of the OCC accept contributed to Utah'south decreasing fatality rate in 2018. This study supports the notion that other strategic health care initiatives (i.e., suicide prevention and improving an individual's social determinants of health) may do good from a collective impact arroyo, especially when community'southward nearly pressing needs are at the intersection of health care delivery and the public's well-beingness.
Acknowledgements:
The research squad would similar to acknowledge and give thanks the treatment teams and clients who were willing to engage in this of import and relentless work.
In addition, this publication would not have been possible without contributions from research interns: John James, Jolynn Jones, and Amy Richards.
References:
1. Abuse CoPMaRStAPO. Hurting Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington DC: National Academies Press; (US: ); 2017. [Google Scholar]
ii. Schieber LZ, Guy GP Jr., Seth P, et al. Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by Land, U.s., 2006–2017. JAMA network open. March 1 2019;ii(3):e190665. [PMC complimentary commodity] [PubMed] [Google Scholar]
three. Mack KA, Jones CM, Ballesteros MF. Illicit Drug Use, Illicit Drug Use Disorders, and Drug Overdose Deaths in Metropolitan and Nonmetropolitan Areas-U.s.. American journal of transplantation : official periodical of the American Society of Transplantation and the American Society of Transplant Surgeons. December 2017;17(12):3241–3252. [PubMed] [Google Scholar]
iv. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crunch: a public health arroyo to an epidemic of addiction. Almanac review of public wellness. March eighteen 2015;36:559–574. [PubMed] [Google Scholar]
v. Scholl 50, Seth P, Kariisa M, Wilson Northward, Baldwin Grand. Drug and Opioid-Involved Overdose Deaths - U.s., 2013–2017. MMWR. Morbidity and mortality weekly report January iv 2018;67(5152):1419–1427. [PMC free commodity] [PubMed] [Google Scholar]
6. Skolnick P The Opioid Epidemic: Crisis and Solutions. Annual review of pharmacology and toxicology. January 6 2018;58:143–159. [PubMed] [Google Scholar]
8. Ahmad FB RL, Spencer MR, Warner Thou, Sutton P. Provisional drug overdose death counts. 2018.
9. Chang DC, Klimas J, Wood E, Fairbairn North. Medication-assisted treatment for youth with opioid use disorder: Current dilemmas and remaining questions. The American journal of drug and alcohol abuse. 2018;44(2):143–146. [PMC costless commodity] [PubMed] [Google Scholar]
10. Connery HS. Medication-assisted treatment of opioid use disorder: review of the show and future directions. Harvard review of psychiatry. Mar-April 2015;23(2):63–75. [PubMed] [Google Scholar]
11. Fullerton CA, Kim 1000, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatric services. Feb 1 2014;65(2):146–157. [PubMed] [Google Scholar]
12. Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatric services. February 1 2014;65(2):158–170. [PubMed] [Google Scholar]
thirteen. Mohlman MK, Tanzman B, Finison G, Pinette Grand, Jones C. Impact of Medication-Assisted Handling for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont. Journal of substance abuse treatment. August 2016;67:ix–14. [PubMed] [Google Scholar]
fourteen. Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retentivity in medication-assisted handling for opiate dependence: A systematic review. Journal of addictive diseases. 2016;35(1):22–35. [PMC costless article] [PubMed] [Google Scholar]
15. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. The American journal of managed care. June 2011;17 Suppl eight:S235–248. [PubMed] [Google Scholar]
sixteen. McCarty D, Perrin NA, Green CA, Polen MR, Leo MC, Lynch F. Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug and alcohol dependence. October one 2010;111(three):235–240. [PMC free article] [PubMed] [Google Scholar]
17. Andrilla CHA, Coulthard C, Larson EH. Barriers Rural Physicians Face up Prescribing Buprenorphine for Opioid Use Disorder. Annals of family unit medicine. July 2017;15(4):359–362. [PMC free article] [PubMed] [Google Scholar]
18. Vestal C In Fighting An Opioid Epidemic, Medication-Assisted Treatment Is Effective But Underused. Health affairs. June 1 2016;35(half-dozen):1052–1057. [PubMed] [Google Scholar]
19. Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What really works? A systematic review. PloS ane. 2017;12(ten):e0186315. [PMC free article] [PubMed] [Google Scholar]
twenty. Jones CM, Campopiano Grand, Baldwin M, McCance-Katz E. National and Land Treatment Need and Capacity for Opioid Agonist Medication-Assisted Handling. American journal of public health. August 2015;105(8):e55–63. [PMC free article] [PubMed] [Google Scholar]
22. Kania JKM. Commonage Impact: Big Scale social alter requires wide cross sector corrdination, yet the social sector remains focused on the isolated intervention of individual organizations. 2011; https://ssir.org/manufactures/entry/collective_impact. Accessed Nov 5,, 2018.
23. Tremblay MC, Martin DH, McComber AM, McGregor A, Macaulay AC. Understanding customs-based participatory research through a social movement framework: a case study of the Kahnawake Schools Diabetes Prevention Projection. BMC public wellness. April 12 2018;18(1):487. [PMC gratuitous article] [PubMed] [Google Scholar]
24. Anderson LM, Adeney KL, Shinn C, Safranek South, Buckner-Brown J, Krause LK. Community coalition-driven interventions to reduce wellness disparities amidst racial and ethnic minority populations. The Cochrane database of systematic reviews. June 15 2015(six):CD009905. [PubMed] [Google Scholar]
25. Koh H Community Approaches to the Opioid Crisis. Jama. October 13 2015;314(fourteen):1437–1438. [PubMed] [Google Scholar]
26. Knighton AJ, Brunisholz KD, Reisig K, Nichols L. Using a Collective Impact Approach to Prevent Prescription Opioid Misuse, Habit, and Overdose Deaths. Quality direction in health care. Oct-Dec 2018;27(four):237–239. [PubMed] [Google Scholar]
28. KB S A collaborative opioid prescribing (CoOP) model linking opioid treatment programs with officebased buprenorphine providers. Addiction Science & CLinical Practice. 2015;10(Suppl one):A63. [Google Scholar]
29. Watkins KE, Ober AJ, Lamp K, et al. Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care: The Peak Randomized Clinical Trial. JAMA internal medicine. October i 2017;177(10):1480–1488. [PMC free commodity] [PubMed] [Google Scholar]
thirty. Weintraub E, Greenblatt AD, Chang J, Himelhoch Due south, Welsh C. Expanding admission to buprenorphine treatment in rural areas with the use of telemedicine. The American journal on addictions. Dec 2018;27(8):612–617. [PubMed] [Google Scholar]
romanfamenceromed.blogspot.com
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751497/
0 Response to "Intermountain Healthcare 738 Reviews - Salt Lake City Ut"
Postar um comentário